Antiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C

J Hepatol. 2014 Nov;61(1 Suppl):S91-7. doi: 10.1016/j.jhep.2014.09.006. Epub 2014 Nov 3.


The treatment of hepatitis C virus (HCV) has made significant advances with the development of new direct-acting antivirals. Nucleotide polymerase inhibitors are one class of these new medications that have been shown to be highly effective, safe and well tolerated as part of an antiviral regimen. Sofosbuvir has become the first drug in this class to be approved for clinical use, supported by results from extensive phase II and phase III clinical trials. This review will further discuss nucleotide polymerase inhibitors, including the data supporting their use as part of interferon-free HCV treatment regimens.

Keywords: Hepatitis C; Nucleoside/nucleotide polymerase inhibitors; Sofosbuvir.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / adverse effects
  • Antiviral Agents / therapeutic use*
  • DNA, Viral / genetics
  • Genotype
  • Hepacivirus / genetics
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / genetics*
  • Humans
  • Nucleic Acid Synthesis Inhibitors / adverse effects
  • Nucleic Acid Synthesis Inhibitors / therapeutic use*
  • Sofosbuvir
  • Treatment Outcome
  • Uridine Monophosphate / adverse effects
  • Uridine Monophosphate / analogs & derivatives
  • Uridine Monophosphate / therapeutic use


  • Antiviral Agents
  • DNA, Viral
  • Nucleic Acid Synthesis Inhibitors
  • Uridine Monophosphate
  • Sofosbuvir